推荐产品
生物源
mouse
品質等級
100
500
共軛
unconjugated
抗體表格
diluted ascites fluid
抗體產品種類
primary antibodies
無性繁殖
AC-1A1, monoclonal
描述
For In Vitro Diagnostic Use in Select Regions (See Chart)
形狀
buffered aqueous solution
物種活性
human
包裝
vial of 0.1 mL concentrate (251M-14)
vial of 0.5 mL concentrate (251M-15)
bottle of 1.0 mL predilute (251M-17)
vial of 1.0 mL concentrate (251M-16)
bottle of 7.0 mL predilute (251M-18)
製造商／商標名
Cell Marque™
技術
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500
同型
IgG1κ
控制
dermatofibroma
運輸包裝
wet ice
儲存溫度
2-8°C
視覺化
cytoplasmic
基因資訊
human ... F13A1(2162)
一般說明
Factor XIIIa is a plasma transglutaminase that is part of the blood coagulation cascade and plays a critical role in stabilizing fibrin networks at the site of an injury to produce a clot. Factor XIIIa is expressed in platelets, megakaryocytes, fibroblast-like cells in the placenta, uterus, and prostate, monocytes and macrophages, and dermal dendritic cells. Anti-Factor XIIIa immunohistochemistry is used to identify fibrohistiocytic neoplasms such as dermatofibroma.
Factor XIIIa is a blood proenzyme that has been identified in platelets, megakaryocyte, and fibroblast-like mesenchymal or histiocytic cells present in the placenta, uterus, and prostate; it is also present in monocytes and macrophages and dermal dendritic cells. Anti- Factor XIIIa has been found to be useful in differentiating between dermatofibroma (90% (+)), dermatofibrosarcoma protuberans (25%(+)), and desmoplastic malignant melanoma (0%(+)). Factor XIIIa positivity is also seen in capillary hemagioblastoma (100%(+)), hemangioendothelioma (100%(+)), hemangiopericytoma (100%(+)), xanthogranuloma (100%(+)), xanthoma (100(+)), hepatocellular carcinoma (93%(+)), glomus tumor (80%(+)), and meningioma (80 % (+)).
Factor XIIIa is a blood proenzyme that has been identified in platelets, megakaryocyte, and fibroblast-like mesenchymal or histiocytic cells present in the placenta, uterus, and prostate; it is also present in monocytes and macrophages and dermal dendritic cells. Anti- Factor XIIIa has been found to be useful in differentiating between dermatofibroma (90% (+)), dermatofibrosarcoma protuberans (25%(+)), and desmoplastic malignant melanoma (0%(+)). Factor XIIIa positivity is also seen in capillary hemagioblastoma (100%(+)), hemangioendothelioma (100%(+)), hemangiopericytoma (100%(+)), xanthogranuloma (100%(+)), xanthoma (100(+)), hepatocellular carcinoma (93%(+)), glomus tumor (80%(+)), and meningioma (80 % (+)).
聯結
Factor XIIIa Positive Control Slides , Product No. 251S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
外觀
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
準備報告
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
其他說明
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
法律資訊
Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
儲存類別代碼
12 - Non Combustible Liquids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
M G Horenstein et al.
The American journal of surgical pathology, 24(7), 996-1003 (2000-07-15)
Routine histology and immunohistochemistry can usually distinguish dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP). DF generally expresses factor XIIIa whereas DFSP generally expresses CD34. The authors report 10 cutaneous fibrohistiocytic lesions combining clinical, histologic, and immunohistochemical features of both DF and
P Abenoza et al.
The American Journal of dermatopathology, 15(5), 429-434 (1993-10-01)
To assess the use of anti-CD34 and anti-factor-XIIIa antibodies for the differential diagnosis of dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP), we stained 40 DFs and 13 DFSPs. A significant population of dendritic and spindle cells was reactive with anti-factor-XIIIa in
Louis P Dehner
The American journal of surgical pathology, 27(5), 579-593 (2003-04-30)
Juvenile xanthogranulomas (JXG) is a histiocytic disorder, primarily but not exclusively seen throughout the first two decades of life and principally as a solitary cutaneous lesion. This study is a retrospective clinical and pathologic review of 174 cases documenting the
A J Demetris et al.
The American journal of surgical pathology, 21(3), 263-270 (1997-03-01)
Epithelioid hemangioendothelioma (EHE) is best considered a vascular neoplasm of intermediate malignancy. Although usually progressive, the clinical course is highly unpredictable. The present communication describes a case of extensive recurrent hepatic EHE, limited to the liver allograft and initially manifest
E J Glusac et al.
The American journal of surgical pathology, 18(6), 583-590 (1994-06-01)
Epithelioid cell histiocytoma is a recently recognized lesion that is considered to be a variant of cutaneous fibrous histiocytoma (dermatofibroma). Ten cases are presented, including their light microscopic, immunohistochemical, and ultrastructural features. Eight of the cases are similar to those
商品
Immunohistochemistry (IHC) techniques and applications have greatly improved, dermatopathology is still largely based on H&E stained slides.This paper outlines ways in which IHC antibodies can be utilized for dermatopathology.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门